VasGene is a clinical-stage company dedicated to the development and commercialization of innovative therapeutics based on the understanding of vascular biology. Breakthroughs in the basic understanding of the vascular networks combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics.
VasGene’s products target signal transduction pathways common to cancer cells and endothelial cells, resulting in powerful anti-cancer agents with multiple modes of action: inhibition of tumor cell growth, anti-angiogenesis, and prevention of tumor cell metastasis.
VasGene has developed an extensive and well-protected intellectual property portfolio covering various therapeutic targets.
Privately held, VasGene is headquartered in Los Angeles, CA.